Overexpressed in aromatase inhibitor resistant estrogen receptor-positive (ER+) breast cancer; reduced in patients with severe hemoglobin reduction after S-1 monotherapy in gastric cancer; differentially expressed between vincristine-resistant and control gastric cancer cell lines. Here, CYP19A1 is linked to breast carcinoma.